INTRODUCTION AND OBJECTIVES: Immune checkpoint inhibitors-based therapy is rapidly developing into an effective treatment option for a surprising range of cancers. Despite the autoimmune or inflammatory immune-mediated adverse effects which have been seen, the responses and overall survival benefits exhibited thus far warrant further clinical development. Lycorine, an alkaloid extracted from plants in the Amaryllidaceae family, which showed a strong anticancer effect by inducing cell lysis of various carcinomas. This study investigated the effectiveness of a combination therapy of lycorine and anti-CTLA-4 in a mouse model of renal cell carcinoma (RCC).
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METHODS: We investigated the anti-tumor efficacy of lycorine in various RCC cell lines including Caki-1, ACHN, KPK-1 and Renca through XTT proliferation, scratch motility, migration and invasion assays. We also discuss that mechanism underlying this anticancer potential with flow cytometry and western blot. Furthermore, luciferase-expressing Renca cells were implanted in the left kidney and the lung of BALB/c mice to develop a RCC metastatic mouse model for investigated the combination therapy effect of lycorine and anti-CTLA-4.
RESULTS: We confirmed the anticancer potential of lycorine in vitro as observed time-dependent inhibition in several RCC cell lines. Moreover, lycorine suppressed the migratory and invasive abilities of Renca cells. The possible mechanism underlying this anticancer potential was cell cycle profile arrest. Lycorine and anti-CTLA-4 additively decreased tumor weight, lung metastasis, and luciferin-stained tumor images. Importantly, these effects were dependent on significantly suppressing regulatory T-cells while upregulating effector T-cells.
CONCLUSIONS: Herein, as we know, it's the first report that lycorine in combination with anti-CTLA-4 inhibited orthotopic and metastatic tumors by downregulating Treg, which was accompanied with upregulation of effector T-cells. Our findings suggest and indicate lycorine as a potent candidate for treating RCC and will serve as an excellent aid for developing a better treatment strategy for the use of immune checkpoint inhibitors in RCC. METHODS: We extracted 109 TILs from 80 patients who underwent surgical resection of RCC, of which 44 TILs were multiply extracted from 15 patients. Each TIL was characterized on the basis of functional T-cell populations using 10 surface marker expressions measured by flow cytometry. Immunological classification was performed by unsupervised clustering analysis of TILs. Comparisons between the surface marker expressions and clinical features were evaluated by logistic regression analysis. Distributions of overall metastasis free survival (MFS) time and recurrence free survival (RFS) was estimated with Kaplan-Meier method and immunological classification was assessed with the log-rank test.
RESULTS: All of the TILs were classified into three groups, which correlated significantly with a substantial number of TILs (p<0.001) and the population of circulating T-cell subsets. Also 35 patients (81.4%) within Group III had lower Fuhrman Grade tumor (G1, 2) whereas 19 patients (47.5%) within Group I, II had higher Fuhrman Grade tumor (G3, 4) (p¼0.028). In multivariate analysis, only Fuhrman grade was also significantly correlated with this immunological classification (odds ratio: 0.253, 95% Confidence Interval (CI): 0.094-0.678, p¼0.006). Importantly, this classification was significantly correlated with overall MFS (hazard ratio (HR): 0.449, 95% CI: 0.243-0.832, p¼0.011) and RFS (HR: 0.475, 95%CI: 0.238-0.948, p¼0.035) in multivariate analysis. Also, we discovered the presence of intra-tumoral diversity in the classification of 3 (20%) of the 15 patients.
CONCLUSIONS: This study showed the presence of classable diversity in the immunological signature of TILs correlated with tumor aggressiveness and prognosis that is observed even within the individual tumor in some patients with RCC.
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